X-Linked Hypophosphatemia Registry – an international prospective patient registry

Raja Padidela1, Gila Nilsson2, Agnès Linglart3, Outs Mäktig1, Sigrid Beck-Nielsen2, Gemma Ariceta4, Dirk Schnabel5, Maria Luisa Brandi6, Annemieke Boot7, Ravi Jandhyala8, Gerd Moeller9, Elena Leutchenko10, and Zuff Murghal11

1Royal Manchester Children’s Hospital, Manchester, UK; 2Karolinska Institutet, Stockholm, Sweden; 3AHLU Biotech Paris Sud Hospital, Le Kremlin Bicêtre, France; 4University of Helsinki, Helsinki, Finland; 5Alder Hey Children’s Hospital, Liverpool, UK; 6University of Southern Denmark, Odense, Denmark; 7Hospital Universitario Marques de Valdecilla, Santander, Spain; 8University of Florence, Florence, Italy; 9University of Groningen, Groningen, The Netherlands; 10University of Kent, Medway, UK; 11Royal Free International, Galveston, UK; 12Hospital Universitario Canarias, Las Palmas, Spain.

OBJECTIVES

A European, multicentre, prospective, non-interventional observational registry has been launched to collect natural history data and characterize the treatment, disease progression and long-term outcomes in children and adults with X-Linked Hypophosphatemia (XLH).

INTRODUCTION

XLH is a rare, inherited disease, a disorder of renal phosphate wasting caused by high circulating levels of fibroblast growth factor 23 (FGF23) that impairs normal phosphate reabsorption in the kidney and production of the active form of vitamin D.1 There is currently no international registry that collects large-scale data on XLH disease progression and treatment outcomes.

METHODS

Design and implementation of the registry (NCT03193476)12 was informed by recommendations from a recent European Medicines Agency, Patient Registries Workshop, (EMA/69716/2017)2 and approved by a steering committee of European experts. The Registry is planned to run for at least 10 years, with an aim to recruit 1200 patients in total; patients with confirmed XLH will be included in the registry under informed consent. As a non-interventional study, all data entered will be from routine practice at the participating sites, measured at baseline and then prospectively at regular intervals; data entry is via an online data capture tool (Castor EDC, Netherlands). The registry will collect demographic variables, age and symptoms at diagnosis and family history, as well as quantitative and qualitative disease markers including: rickets, bone deformities, growth, oral health, muscular function, quality of life, phosphate wasting, alkaline phosphatase; and complications including nephrocalcinosis, hyperparathyroidism, hearing loss and neurological features. No data nor investigations are mandated by the protocol.

RESULTS

The XLH Registry has currently recruited 50 patients from 50 sites across the UK, France, Denmark, Germany, Sweden and Italy. National regulatory approval is pending in The Netherlands, Belgium and Norway, and a total of 62 sites are expected to be live by December 2018.

CONCLUSIONS

✓ The XLH Registry will facilitate the generation of epidemiological data that will enhance and improve understanding of the natural history and disease burden of XLH, as well as long-term outcomes in patients with XLH
✓ The XLH registry will help describe the effectiveness and safety of treatments used to manage the symptoms and signs of XLH
✓ The XLH registry will support development of future XLH treatment guidelines and inform best practice

References:

Presented at the European Society for Paediatric Endocrinology (ESPE) 2018 meeting; Athens, Greece; 27-29 September 2018.

Figure 1. FGF23-vitamin D phosphate axis. PME (Phosphate Regulating Endopeptidase Homolog, X-linked), CYF2A1 (Cytochrome P450 family 24 subfamily A member 1), CYP27B2 (Cytochrome P450 family 27 subfamily B member 2), PTH (Parathyroid hormone), NPT2C and NPT2A (renal sodium-dependent phosphate co-transporter genes).

Figure 2. The signs, symptoms, sequelae, and long-term consequences of XLH in pediatric (left) and adult (right) patients.

Figure 3. XLH Registry Design and Implementation Timeline

Figure 4. XLH Patient Recruitment per Centre

Figure 5. XLH Patient Recruitment per Country by August 2018

Figure 6. XLH Registry Patient Recruitment